Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
In a stepped wedge trial of 2348 distressed patients and caregivers calling a cancer telephone support service, structured distress screening and referral did not increase referral uptake or reduce distress versus usual care; intervention fidelity was poor.
RCTn = 2,348
Fradgley et al. The impact of structured care versus usual care on service uptake and distress among distressed callers to a cancer telephone support service: outcomes of the START stepped wedge trialMeta-analysis of 14 observational studies (464 biologic treatment lines) in pityriasis rubra pilaris: pooled complete/near-complete response 0.36, any response 0.73. No significant difference between TNF, IL-17 and IL-23 pathway inhibitor classes (p=0.057); AEs in 12/183 courses.
Meta-analysisn = 464 biologic therapeutic lines
Tartaglia et al. Biologic Therapy in Pityriasis Rubra Pilaris: Systematic Review and Meta-analysis with Class-based ComparisonsIn 393 patients with early Parkinson disease analysed (410 randomised), 52 weeks of nicotinamide riboside did not help and worsened MDS-UPDRS total score vs placebo (adjusted mean difference 2.72 points; P=.02); non-motor symptom burden also worsened more.
RCTn = 410
Brakedal et al. Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical TrialIn 353 patients with LVEF 36–50% and CMR-defined myocardial scar, a primary prevention ICD did not reduce sudden cardiac death or haemodynamically significant ventricular arrhythmia vs a loop recorder over a median 6.3 years (7.8% vs 9.2%; HR 0.76).
RCTn = 353
Selvanayagam et al. Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%: The CMR GUIDE Randomized Clinical TrialIn 323 patients with persistent AF undergoing rheumatic mitral valve surgery, biatrial Cox-Maze IV ablation gave more 12-month freedom from atrial tachyarrhythmias off antiarrhythmics than left atrial maze (78.7% vs 68.6%), with non-inferior pacemaker rates (97.0% vs 98.1% free).
RCTn = 323
Li et al. Biatrial Versus Left Atrial Maze Ablation During Cardiac Valve Surgery for Persistent Atrial Fibrillation: The ABLATION TrialIn a three-arm RCT of 255 patients with cancer-related fatigue, thunder-fire moxibustion plus Yiqi Wenyang Tincture lowered week-6 Revised Piper Fatigue Scale scores vs moxibustion alone (adjusted difference −0.459) and modestly raised global quality of life (2.552).
RCTn = 255
Liu et al. Clinical outcomes of Thunder-fire moxibustion with or without Yiqi Wenyang Tincture for cancer-related fatigue: a randomized controlled trialIn 64 inpatients with advanced cancer (42 completed follow-up), mechanical bathing every other day vs once weekly for 1 week did not significantly reduce overall symptom distress; exploratory analyses suggested early gains in breathlessness and well-being.
RCTn = 64
Hsu et al. Frequent mechanical bathing as integrative supportive care for patients with advanced cancer: a randomized controlled trialIn a phase 1 randomised placebo-controlled trial in 56 healthy adults, EDI048, a Cryptosporidium PI(4)K inhibitor, was well tolerated up to 400 mg twice daily for 5.5 days, with few mostly mild adverse events and minimal systemic exposure.
RCTn = 56
Jain et al. A First-in-Human Phase 1 Clinical Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of EDI048, a Novel Promising Agent to Treat Enteric CryptosporidiosisIn a first-in-human trial, 51 healthy adults received single intravenous GB-0669 (100–2400 mg; n=36) or placebo (n=15). It was well tolerated with only mild adverse reactions, a half-life of 54 days, and dose-dependent virus neutralisation at 600 and 1200 mg.
RCTn = 51
Borriello et al. Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem HelixIn a phase II trial of 41 patients with resectable head and neck squamous cell carcinoma, neoadjuvant camrelizumab plus apatinib gave a 29.3% major pathologic response rate. Two cycles vs one: 40% vs 23.1% (P=0.300, non-significant). Grade ≥3 toxicity occurred in 2.4%.
RCTn = 41
Jie et al. A Phase II Trial of Chemotherapy-Free Neoadjuvant Camrelizumab plus Apatinib for Resectable HNSCC: Pathologic Response and Vascular-Immune Cross-talk